Objective To describe paraneoplastic neuronal intermediate filament (NIF) autoimmunity.
Paraneoplastic neurologic disorders are initiated as an immune response directed against one or more tumor-expressed neural autoantigens. 1 Certain neural immunoglobulin G (IgG) paraneoplastic autoantibodies are disease-specific diagnostic biomarkers. Some antibodies likely have pathogenicity derived from events downstream of IgG binding to the extracellular domain of a neural protein (such as the GluN1 subunit of the NMDA receptor). 2 Other antibodies, such as anti-Hu or anti-Yo, which are reactive with nuclear or cytoplasmic antigens, despite not being pathogenic, can nonetheless be specific biomarkers of cytotoxic T-cell-mediated autoimmune neurologic disorders. 1 Recently, our group described a class of steroid-responsive inflammatory CNS disorders unified by glial fibrillary acidic protein (GFAP) antibody, a cytoplasmic type III intermediate astrocytic filament. 3, 4 The diagnosis now routinely is made in our clinical laboratory by identification of GFAP-IgG in CSF by tissue-based indirect tissue immunofluorescence assay (IFA) and confirmation by a cell-based assay (CBA) using a GFAPtransfected cell line.
Neuronal intermediate filament (NIF) antibodies have been reported previously among patients with various diseases and healthy controls, generally when tested for by a single assay type such as Western blot or ELISA. [5] [6] [7] Here, we report NIF autoimmunity detected among patients referred for broad screening of neural antibodies by IFA, who had confirmation of NIF specificity by CBAs. Specificities included mature NIF forms (α internexin [αIN] , neurofilament light chain [NfL] , neurofilament medium chain [NfM] , neurofilament heavy chain [NfH] , and peripherin), but not immature forms (vimentin or nestin) or GFAP. In particular, we focus on a group of patients who had an NIF-IgG profile that included NfL-IgG accompanied by paraneoplastic CNS autoimmunity (usually cerebellar ataxia, encephalopathy, or both) in the context of neuroendocrine neoplasia.
Methods
Standard protocol approvals, registrations, and patient consents The Mayo Clinic Institutional Review Board approved human specimen acquisition and review of patients' histories (IRB ).
Study population
The Mayo Clinic Neuroimmunology Laboratory tested by tissue IFA, on a service basis, 616,025 serum and CSF specimens submitted for patients undergoing workup for a suspected paraneoplastic neurologic or autoimmune encephalitic illness. Either of 2 distinctive neuronal filamentous patterns of IgG reactivity was observed by IFA in serum, CSF, or both in 85 patients.
Control specimens tested by both IFA and CBAs (257 total: 237 sera, 20 CSF) were as follows: sera from 33 healthy controls, 63 cancer patients without neurologic symptoms (30 patients with small cell lung carcinoma, 23 patients with hepatocellular carcinoma, and 10 patients with Merkel cell carcinoma), and 20 patients with a diagnosis of a paraneoplastic neurologic disorder (anti-Hu, anti-Yo, 10 patients each), and specimens from 122 patients with diseases in whom neurofilament antibodies were previously reported in the literature including Creutzfeldt-Jakob disease (CJD; 30 sera and 10 CSF), type I diabetes mellitus (30 sera), CNS systemic lupus erythematous (11 sera and 1 CSF), multiple sclerosis (MS; 20 sera and 9 CSF), and amyotrophic lateral sclerosis (ALS; 30 sera). Some historical noncancer control specimens previously tested by IFA only (354 total) were 288 healthy adult donor sera and 119 CSF from adult patients with either normal pressure hydrocephalus (66) or miscellaneous nonautoimmune neurologic disorders (53; 21 adult, 32 pediatric).
Antigen characterization
An algorithm demonstrating the strategy for antibody characterization and testing is outlined in figure 1. Patient and control serum and CSF specimens, and commercial monoclonal antibodies, were tested by indirect IFA on cryosections (4 μm) of adult mouse tissues: cerebellum, midbrain, cerebral cortex, striatum, hippocampus, kidney, and gut. 4 Cutoff values of ≤1:120 for serum and ≤1:2 for CSF are long-established and clinically validated in the Mayo Clinic Neuroimmunology Laboratory. The detailed procedures for this and the following are described in data available from Dryad (appendix e-1, doi.org/10.5061/dryad.43vc3c6): (1) antibody characterization (Western blotting, immunoprecipitation, mass spectrometry, antibody purification, and dual staining of tissues and cells with patient specimens and commercial IgGs); (2) NIF antibody profile testing (development of NIF-specific cell lines in-house for CBA); (3) standard clinical neural antibody testing performed; and (4) staining of tumor tissue.
NIF-IgG profile determination by CBA Cells from stably transfected NIF-expressing cell lines were plated in 8-well poly-D-lysine-coated chamber slides (Corning; Corning, NY), fixed (4% paraformaldehyde, 15 minutes), Glossary αIN = α internexin; ALS = amyotrophic lateral sclerosis; CBA = cell-based assay; CJD = Creutzfeldt-Jakob disease; GFAP = glial fibrillary acidic protein; IFA = immunofluorescence assay; IgG = immunoglobulin G; MS = multiple sclerosis; NfH = neurofilament heavy chain; NfL = neurofilament light chain; NfM = neurofilament medium chain; NIF = neuronal intermediate filament; PBS = phosphate-buffered saline.
and permeabilized (0.2% Triton-X-100, 10 minutes). Normal goat serum (10%) was applied for 30 minutes to block nonspecific IgG binding. Patient or control serum (1:600 dilution) and CSF (1:5) were added to the cells for 90 minutes at room temperature. The CBA dilution of 1:600 was the optimized dilution whereby all our patient sera (NIF-IgGpositive by IFA) remained robustly positive (having also been tested with the same results at 1:100, 1:200, and 1:400), with the least amount of nonspecific staining among controls. All of our patient sera and CSF that were IFA-positive remained unambiguously positive at 1:600 and 1:5, respectively, by CBAs.
Cells were washed in phosphate-buffered saline (PBS) and secondary antibody (TRITC-conjugated goat antihuman IgG, 1:200) was applied for 45 minutes. After washing cells in PBS, slides were mounted in Prolong Gold anti-fade reagent containing 4,6-diamidino-2-phenylindole (Molecular Probes, Eugene, OR).
Statistical methods
Neurologic disorder type and cancer frequency and histologic type for NIF-IgG patient groups were compared by Fisher exact test (JMP).
Data availability
Data available from Dryad, doi.org/10.5061/dryad.43vc3c6.
Results
Between January 1, 1993, and April 30, 2017, the Mayo Clinic Neuroimmunology Laboratory identified 2 distinctive neuronal filamentous-appearing patterns of IgG reactivity by IFA in serum or CSF of 85 patients (with 90 available specimens: Figure 1 Algorithm for antigen characterization and 2-step algorithm for the serologic diagnosis of neuronal intermediate filament (NIF) autoimmunity serum, 65; CSF, 25) among 616,025 serum and CSF specimens tested (0.014%). Sixty-five patients with both clinical information and ≥1 specimens available were included.
Autoantibody characterization
Tissue distribution of immunoreactivity Sera (48) and CSF specimens (19) from all 65 patients intensely stained neuronal cytoplasmic filaments throughout the CNS and enteric mouse tissue composite (figure 2, A.a-C.a, E.a-G.a). Non-neural renal and gastrointestinal parenchymal tissues were nonreactive (figure 2, C.a and G.a). In the cerebellum, immunostaining of cerebellar granular layer and peri-Purkinje cell regions was intense in all 65 patients. In 42 patients, immunostaining additionally produced a blush that faded in intensity through the molecular layer, from deep (adjacent to the Purkinje cell layer) to superficial regions (pattern 1, exemplified by patient 21; figures 2A and 3A). Abbreviations: αLH = α internexin, light chain and heavy chain immunoglobulin Gs; αLHP = α internexin, light chain, heavy chain, and peripherin immunoglobulin Gs; αLM = α internexin, light chain and medium chain immunoglobulin Gs; αLMH = α internexin, light chain, medium chain, and heavy chain immunoglobulin Gs; αLMHP = α internexin, light chain, medium chain, heavy chain, and peripherin immunoglobulin Gs; αLP = α internexin, light chain and peripherin immunoglobulin Gs; CASPR2 = contactin-associated protein 2; CRMP-5 = collapsin-response mediator protein-5; GAD65 = glutamic acid decarboxylase, 65 kilodalton isoform; IFA = immunofluorescence assay; IgG synth = immunoglobulin G synthesis rate; LGI1 = leucine rich glioma inactivated-1; LH = light chain and heavy chain immunoglobulin Gs; LMH = light chain, medium chain, and heavy chain immunoglobulin 
Absorption experiments
Tissue IFA staining patterns produced by sera from patient 22 (pattern 1, αIN-IgG positive only) and patient 28 (pattern 2, NfH-IgG positive only) were specifically abolished by preincubating sera with recombinant human αIN and NfH, respectively (figure e-2, doi.org/10.5061/dryad. 43vc3c6). However, recombinant human αIN had no effect on NfH-IgG reactivity of serum from patient 28, and NfH had no effect on αIN-IgG reactivity of serum from patient 22 (data not shown). Tissue IFA staining produced by sera from 3 patients with diverse NIF-IgG profiles (patients 1, 12, and 17) were unaffected by preincubating sera with different concentrations of the polypeptide region of coil 2B rod domain, an identical region common to all of αIN, NfL, NfM, and NfH (data not shown), consistent with the patient's NIF-IgG profile being polyclonal rather than monoclonal.
Cell-based assay

HEK293 cells were transfected with expression plasmids encoding individual human intermediate NIFs tagged with GFP. Specificity of the NIF cell lines was confirmed by
Western blotting a lysate of each using commercial NIFspecific IgGs (data not shown). Commercial NIF-specific IgGs, control and patient sera, and CSF specimens were evaluated by indirect immunofluorescence after fixation and permeabilization of cells ( figure 5 and figure e-3, doi.org/10. 5061/dryad.43vc3c6). IgG to another NIF (peripherin-IgG) was also tested for by the same method. This was done because our patients produced staining of myenteric and renal autonomic nerves indistinguishable from peripherin-IgG (figure e-4, doi.org/10.5061/dryad.43vc3c6) and most patients had more than 1 of the other NIF-IgGs detected. (6%), 1 of 30 with CJD (3%), 1 of 29 with MS (3%), and 1 of 30 with ALS (3%). Only 2 control sera were positive by both IFA and CBA; both had small cell carcinoma (both had pattern 1 on IFA). All CSF controls were negative by IFA and CBAs. All 354 historical control specimens screened by tissue IFA alone were negative. 
NfL-IgG-positive patients have CNS paraneoplastic autoimmunity
There were 21 patients with a profile of NIF-IgGs that included NfL-IgG. All had pattern 1 by IFA, and 3 were positive in CSF only. The median number of NIF-IgGs positive was 4 (range 2-5). Eight were evaluated neurologically at Mayo Clinic.
Cancers contemporaneous with the onset of neurologic symptoms were detected in 16 of 21 patients (positive predictive value of 77%, table 1), 2 whose neurologic symptoms started after anti-T-cell regulatory checkpoint inhibitor therapy for cancer. Thirteen of the remaining 14 cancers were detected within 3 months after serum or CSF draw for antibody testing. Carcinomas of neuroendocrine lineage (10; 49% of all 21 patients) were most common: small cell carcinoma (5), Merkel cell carcinoma (3, metastatic and of unknown skin primary in 2), pancreatic neuroendocrine (1), and metastatic neuroendocrine of unknown primary (1). Other neoplasms included hepatocellular carcinoma (2), non-Hodgkin lymphoma (2), uterine leiomyosarcoma (1), and non-small cell lung carcinoma (1). Duration of follow-up was short (median, 2 months; range 0-36).
Nineteen of 21 patients had subacute onset neurologic disorders affecting the CNS (table 1) . The other 2 had either peripheral neuropathy (in the context of chemotherapy for T-cell lymphoma, bone marrow transplant, and graft-versushost disease) or carcinomatous meningitis (in the context of small cell carcinoma). Neurologic diagnoses among the 19 patients were cerebellar ataxia (11; 58%), encephalopathy (11; 58%), and myelopathy (2; 11%). Four patients had encephalopathy and cerebellar ataxia coexisting (22%), 3 patients had encephalopathy and cranial neuropathies coexisting (16%), and 1 had encephalopathy and myelopathy coexisting (5%). Other coexisting disorders were peripheral neuropathy (2) and dysautonomia (1). Those with ataxia had rapidly progressive gait and coordination difficulties and appendicular cerebellar signs. Those with encephalopathy had subacute onset delirium and memory difficulties in all, and psychiatric symptoms in 4. Only 1 patient had classical limbic encephalitis. One 47-year-old woman with encephalitis had NMDA-receptor IgG coexisting, accompanied by small cell lung carcinoma, rather than ovarian teratoma. Overall, this NIF-IgG profile was 100% specific for having ≥1 of encephalopathy, cerebellar ataxia, or cancer.
At presentation, 4 of 9 patients with data available had normal head MRI scans. Abnormal findings (figure e-5, doi.org/10. 5061/dryad.43vc3c6) were cerebellar atrophy in 2 ataxic patients (1 also had T2 signal abnormalities), bilateral hippocampal T2 signal abnormalities in a patient with limbic encephalitis, and cranial nerve enhancement in 2 patients with cranial neuropathies (1 with encephalomyelopathy also had diffuse brain and cord T2 signal abnormalities). Seven of 10 patients with data available had inflammatory CSF (elevated lymphocyte-predominant white cell counts or CSF-restricted oligoclonal bands) ( anterior horn cell disorders, 2; optic neuropathies, 2; chorea, 2; and one each of demyelinating disease, myopathy, and retinopathy. These patients also less frequently had cancer (15/44 vs 16/21, p = 0.003), and were less likely to have cancers of neuroendocrine lineage (1/44 vs 10/21, p < 0.0001). The median NIF antibody-positive number was lower than in the NfL-IgG cases (2; range, 1-3), and NF-H-IgG predominated.
Merkel cell tumor pathology Patient 8, with severe pancerebellar ataxia, was seropositive for all NIF-IgGs with the exception of peripherin IgG. Her enlarged groin lymph node had immunohistochemical findings characteristic of Merkel cell carcinoma with diffuse reactivity for both cytokeratins (AE1/AE3 and CK-20) and neuroendocrine cells (synaptophysin). In addition, immunostaining was positive for αIN, NfL, NfM, and NfH, but not peripherin ( figure 6 ).
Discussion
We have described a class of paraneoplastic neurologic disorder, diagnosable by screening serum or CSF for a distinctive pattern of NIF-IgG by IFA (pattern 1), and then confirming NIF specificity by detecting a profile of at least 2, and usually ≥4 NIF-IgGs, that always includes NfL-IgG. Subacute onset and rapidly progressive CNS disorders (usually cerebellar ataxia or encephalopathy or both) were encountered in affected patients. Consistent with the diffuse nervous system distribution of NIF antigens, occasional patients had coexisting myelopathy, cranial neuropathies, retinopathy, or peripheral neuropathy. Seventy-seven percent of those 21 patients had cancer, most commonly neuroendocrine lineage neoplasms (small cell, pancreatic, or Merkel cell carcinomas). This may be an underestimate given the short duration of follow-up available and limited data available on non-Mayo Clinic patients. Supportive findings for an autoimmune diagnosis in our 21 NfL-IgG-positive patients included an inflammatory CSF in 7 of 10 with data available. Most had other clues to CNS inflammation in CSF or on MRI. Cancer specificity was supported by detection of NIF-IgG autoimmunity coexisting in a patient over 40 years of age with typical NMDAR encephalitis, but who had small cell carcinoma rather than the classically described ovarian teratoma.
2 Antigen specificity was supported by the patient whose Merkel cell carcinoma had a NIF staining profile matching her NIF-IgG serologic profile. Affected patients, when treated with immunotherapy, generally improved, while those who went untreated died. Consistent with our experience, cerebellar degeneration has been reported as a paraneoplastic neurologic accompaniment of Merkel cell carcinoma. 9, 10 Another report demonstrated neurofilament triplet protein reactivity in sera from patients with paraneoplastic retinopathy accompanying small cell carcinoma. 11, 12 Our series also adds to the literature of paraneoplastic neurologic disorders arising during checkpoint inhibitor therapy for cancer. 13 We also encountered 44 patients without NfL-IgG with less specific neurologic and cancer findings, which will require future study. Serologically, those patients were distinct from the NfLIgG-positive cases: their specimens usually produced a neurofilamentous pattern of staining on IFA resembling NfH-IgG (pattern 2) and had a more limited NIF-IgG profile by CBAs (just 1-2 antibodies positive, usually including NfH-IgG). While measurement of individual NIF proteins (such as phosphorylated NfH in serum and CSF of patients with ALS) has significance for neurodegenerative disease, 14, 15 measurements of individual NIF antibodies by ELISA, Western blot, or CBAs alone have unclear significance. [6] [7] [8] [16] [17] [18] [19] [20] [21] [22] Our experience of testing large numbers of controls yielded occasional positive results in serum in CBA only, among both healthy controls and patients with diverse disease states (such as MS, ALS, and CJD). In contrast, only 2 controls tested positive by both IFA and CBA. Both had small cell carcinoma without neurologic disease. Similarly, in our neurologic patients, diagnostic specificity for a paraneoplastic neurologic disorder required both positivity by screening with tissue IFA for pattern 1 and subsequent molecular confirmation by CBAs of an NIF-IgG profile that included NfL-IgG. At this early stage, evaluation of CSF in addition to serum appears to improve testing sensitivity.
αIN, NfL, NfM, and NfH are Class IV neuronal intermediate filaments widely expressed in mature central, peripheral, and autonomic neurons. 23 Peripherin is a type III NIF expressed predominantly in the peripheral nervous system. 24 NIFs support structure and functions such as transport and conduction of neuronal dendrites and axons throughout the nervous system. [25] [26] [27] NfL, NfM, and NfH, so called because of their molecular weights, are obligate heteropolymers, known as neurofilament triplet proteins. As experienced with GFAP IgG, overexpression of a single GFP-tagged NIF in HEK-293 cells, without other NIF binding partners present, results in GFP-positive NIF inclusion bodies, rather than well-formed neurofilamentous tertiary structures. This did not hinder CBA interpretation. 3, 4 As is usually the case for paraneoplastic neurologic disorders, it is likely that NIF autoimmunity is cytotoxic T cell-mediated, and not antibody-mediated, given the exclusively cytoplasmic localization of NIF proteins. 1 In normal skin, nerve fibers immunoreactive for NIFs are restricted to free nerve endings in the epidermis, dermal papilla, and Meissner corpuscles. 28, 29 In contrast, neurofilament triplet proteins and αIN expression were diffusely expressed in metastatic cutaneous neuroendocrine (Merkel cell) neoplasm from patient 8 with cerebellar ataxia. The tumor's NIF immunoreactivity matched the patient's serum NIF-IgG profile (positive for 4 of 5, excluding peripherin). Consistent with the diversity of oncologic accompaniments encountered in our patients, NIF proteins are known to be expressed in lung carcinomas (both small cell and non-small-cell), neuroendocrine neoplasms, breast adenocarcinoma, sarcomas, and neuroblastomas. [30] [31] [32] [33] [34] [35] Though triton-insoluble, obtaining a NIF-enriched substrate for our Western blot was assured by solubilizing rat spinal cord in 8M urea. 24 Neuronal precursor cells express the intermediate filaments nestin (type VI) and vimentin (type III) but their expression declines when these cells exit the cell cycle and differentiate into neurons. 36 Tissue staining with commercial nestin and vimentin antibodies did not colocalize with our patient NIFIgGs. All intermediate filaments are composed of a central α-helical rod domain flanked by N-(head) and C-(tail) terminals. 37 In the rod domain, polypeptide dimers associate in parallel (known as coiled-coils). Differential amino acid sequences of nonconserved coiled-coil and C-terminal regions allow for diversity of structure and function of intermediate filaments. 37, 38 Consistent with a polyclonal response against NIF tertiary intermediate filament structures, our patients had diverse NIF-IgG profiles, and did not have a monoclonal reactivity with a highly conserved region common to all NIFs.
Patients with subacute onset of encephalopathy, ataxia, or myelopathy can undergo screening of serum and CSF by immunohistochemical techniques for both common and rare causes of paraneoplastic neurologic autoimmunity, including the pattern 1 of neurofilamentous staining we describe. Where CBAs confirm a profile of NIF-IgGs that includes positivity for NfL-IgG, a search for cancer (in particular those of neuroendocrine lineage) should be undertaken, and a trial of immunotherapy considered.
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